Bernd R. Seizinger

Medicine · Health Sciences

50h-index10.1kcitations117works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neurofibromatosis and Schwannoma Cases(27), Neuropeptides and Animal Physiology(26), Receptor Mechanisms and Signaling(16), Neuroblastoma Research and Treatments(16), Cancer-related Molecular Pathways(15)

Publications117 total

Announcement / Erratum
Neuroendocrinology·2008Open Access
GPC Biotech AG
Gabler Verlag eBooks·2005
GPC Biotech AG
Gabler Verlag eBooks·2004
DNA microarray technology and antimicrobial drug discovery
Pharmacogenomics·2000· 23 cited
Integrated bacterial genomics for the discovery of novel antimicrobials
Drug Discovery Today·2000· 17 cited
Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity
Oncogene·1999· 140 cited
PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes
Oncogene·1999· 253 cited
The p53/IGF-1 receptor axis in the regulation of programmed cell death
Endocrine·1997· 34 cited
The p53 tumor suppressor targets a novel regulator of G protein signaling
Proceedings of the National Academy of Sciences·1997· 97 citedOpen Access
A Kindred with a Variant of Multiple Endocrine Neoplasia Type 1 Demonstrating Frequent Expression of Pituitary Tumors but Not Linked to the Multiple Endocrine Neoplasia Type 1 Locus at Chromosome Region 11q13<sup>1</sup>
The Journal of Clinical Endocrinology & Metabolism·1997· 35 citedOpen Access
Chromosome 17 Allelic Loss and NF1-GRD Mutations Do Not Play a Significant Role as Molecular Mechanisms Leading to Melanoma Tumorigenesis
Journal of Investigative Dermatology·1996· 14 cited
Potent, Cell Active, Non-Thiol Tetrapeptide Inhibitors of Farnesyltransferase
Journal of Medicinal Chemistry·1996· 79 citedOpen Access
Development of Highly Potent Inhibitors of Ras Farnesyltransferase Possessing Cellular and<i>in Vivo</i>Activity
Journal of Medicinal Chemistry·1996· 88 citedOpen Access
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
Proceedings of the National Academy of Sciences·1995· 364 citedOpen Access
Induction of the growth inhibitor IGF-binding protein 3 by p53
Nature·1995· 877 cited
Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
PubMed·1995· 112 cited
Regulation of the Sequence-specific DNA Binding Function of p53 by Protein Kinase C and Protein Phosphatases
Journal of Biological Chemistry·1995· 197 citedOpen Access
Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: implications for the potential organization of the human von Hippel-Lindau disease gene.
PubMed·1995· 55 cited
Ras farnesylation as a target for novel antitumor agents: Potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase
Drug Development Research·1995· 69 cited
Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes.
Proceedings of the National Academy of Sciences·1994· 83 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Nikolai Kley(10), James F. Gusella(8), Andreas von Deimling(8), Robert L. Martuza(6), David N. Louis(6), A. Herz(6), Guy A. Rouleau(5), Albert Herz(5), Leonard Buckbinder(4), Randy Talbott(4), Richard Y. Chung(4), Jean M. Whaley(4), Michele R. Filling‐Katz(4), V. Höllt(4), Ning Yan(4), Veeraswamy Manne(4), Volker Höllt(4), Susana Velasco-Miguel(3), Laurie J. Ozelius(3), Jonathan L. Haines(3)